Send to

Choose Destination
Electron Physician. 2017 Oct 25;9(10):5402-5418. doi: 10.19082/5402. eCollection 2017 Oct.

Prevalence of metabolic syndrome in Iran: A meta-analysis.

Author information

PhD, Associate Professor, Social Determinants of Health Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
Msc, Student Research Committee, Ilam University of Medical Sciences, Ilam, Iran.
PhD, Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
MD, Poostchi Ophthalmology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
MSc, Department of Paramedical Sciences, Faculty of Emergency Medicine, Alborz University of Medical Sciences, Karaj, Iran.
MD, Assistant Professor, Department of Cardiology, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran.



Metabolic syndrome) MetS( is a complex risk factor which increases the risk of cardiovascular diseases and type 2 diabetes. There are many studies with various populations and results about the prevalence of MetS in Iran; in order to authenticate these studies and have an overall estimation of its prevalence in Iran, performing a meta-analysis seems to be necessary.


This study aimed to investigate the prevalence of MetS and its components in Iran via meta-analysis method.


All associated published papers in national and international journals of PubMed, Scopus, Web of Science, Magiran, Iranmedex, Science Direct, Medlib, and SID databases were searched from January, 2000 to October, 2016. All types of studies, including local and national surveys that reported the prevalence of MetS among healthy populations in Iran were reviewed. The effects of age, sample size and publication date as possible sources of heterogeneity among the study findings was examined by meta-regression. P-values less than 0.05 were considered as significant in heterogeneity tests. All analysis was done by R Ver. 3.2.1 and STATA (version 10).


Seventy eligible studies were selected for meta-analysis. The overall estimation of MetS prevalence was 25% (95% CI: 22-29%) based on the Adult Treatment Panel III (ATP III) criteria, 30% (95% CI: 25-36%) according to the International Diabetes Federation (IDF), and 39% (95% CI: 26-52%) based on the Joint Interim Societies (JIS) criteria. The prevalence of MetS was lower in men than in women (26.9% versus 35.7%). The prevalence of various MetS components including High TG (triglyceride), Low HDL-C, High BP and High FBS (fasting blood sugar) was 43%, 54%, 38% and 22% among the adult population.


Findings from the present meta-analyses study displayed a high prevalence of metabolic syndrome in Iran, especially in women, which increases with age in both sexes. It alerts health care providers and policy makers to find solutions in order to take action to reduce MetS risk in society.


Components; Dysmetabolic syndrome; Iran; Meta-analysis; Population groups; Prevalence

Conflict of interest statement

Conflict of Interest: There is no conflict of interest to be declared.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center